|Table of Contents|

Significance of C-ROSE after EBUS-TBNA sampling combined with lung serum tumor markers in pathological classification and classification transformation of lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 01
Page:
51-59
Research Field:
Publishing date:

Info

Title:
Significance of C-ROSE after EBUS-TBNA sampling combined with lung serum tumor markers in pathological classification and classification transformation of lung cancer
Author(s):
CHENG Wenliang; LI Rong; ZHAO Dehua; LI Jie; FANG Yuwei; LI Yiqing; GE Xiaojun
Department of Clinical Laboratory,the Second Affiliated Hospital of Zunyi Medical University,Guizhou Zunyi 563000,China.
Keywords:
C-ROSE; serum tumor marker; lung cancer; pathological type
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2025.01.009
Abstract:
Objective:To explore the benefits of combining C-ROSE with pulmonary serum tumor markers for lung cancer pathologic classification and classification transformation.Methods:A total of 125 patients who underwent C-ROSE examination after EBUS-TBNA sampling in our hospital from October 2021 to July 2023 were collected,including 33 cases of lung squamous cell carcinoma (LUSC),40 cases of lung adenocarcinoma (LUAD),11 cases of large cell poorly differentiated lung carcinoma (LCLC) and 41 cases of small cell poorly differentiated lung carcinoma (SCLC).The diagnostic positive rates of C-ROSE and lung serum tumor markers were compared in different pathological types of lung cancer after EBUS-TBNA sampling alone or in combination.Results:C-ROSE can improve the sampling qualification rate of LUSC (72.7%),LUAD (85.0%),LCLC (63.6%),SCLC (53.1%) and other types of lung cancer (P＜0.05).At the same time,SCCAg was the dominant lung serum tumor marker in LUSC (sensitivity 87.9%,specificity 82.6%,AUC=0.907,P＜0.05),and C-ROSE combined with SCCAG could increase the positive rate of diagnostic efficacy (87.9%,P＜0.05).CEA was the dominant pulmonary serum tumor marker in LUAD (sensitivity 62.5%,specificity 80.0%,AUC=0.733,P＜0.05).Combined with C-ROSE could increase the positive rate of diagnostic efficacy (97.5%,P＜0.05).ProGRP+NSE was the dominant serum tumor marker in SCLC (sensitivity 85.4%,specificity 95.2%,AUC=0.943,cut-off=134.94,P＜0.05).ProGRP+NSE combined with C-ROSE can improve positive rate of the diagnostic efficacy (90.2%,P＜0.05).The diagnostic value of NSE/ProGRP was the highest in LCLC (sensitivity 90.9%,specificity 82.9%,AUC=0.894,cut-off=0.332,P＜0.05).The combination with C-ROSE could improve the positive rate of diagnostic efficacy (100.0%,P＜0.05).Conclusion:After EBUS-TBNA sampling,C-ROSE combined with lung serum tumor markers can improve the positive rate of early diagnosis of different pathological types of lung cancer and help to warn the type change.

References:

［1］QIU HB,CAO SM,XU RH.Cancer incidence,mortality,and burden in China:a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020［J］.Cancer Communications （London,England）,2021，41（10）：1037-1048.
［2］董懂,黄意恒,张亚杰,等.《中华医学会肺癌临床诊疗指南（2023版）》解读［J］.中国胸心血管外科临床杂志,2023,30(11):1533-1538. DONG D,HUANG YH,ZHANG YJ,et al.Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition):An interpretation ［J］.Chinese Journal of Clinical Thoracic and Cardiovascular Surgery,2023,30（11）:1533-1538.
［3］黄桂玲,台婧,张超,等.7种血清肿瘤标志物单独及联合应用在不同类型肺癌早期诊断中的价值［J］.中国老年学杂志,2024,44(04):792-795. HUANG GL,TAI J,ZHANG C,et al.The value of seven serum tumor markers alone and in combination in the early diagnosis of different types of lung cancer［J］.Chinese Journal of Gerontology,2024,44（04）：792-795.
［4］YAN Y,WANG ZL,YAN WP,et al.Endobronchial ultrasound-guided transbronchial needle aspiration in patients with previously treated malignancies:diagnostic performance and predictive value［J］.BMC Pulmonary Medicine,2022,22（1）：470.
［5］张天明,王虹,黄晖蓉.虚拟导航支气管镜联合快速现场细胞学评价对肺外周病变良、恶性的诊断价值［J］.临床内科杂志,2022,39(7):448-452. ZHANG TM,WANG H,HUANG HR.Value of virtual bronchoscopic navigation combined with rapid on-site evaluation for the diagnosis of benign and malignant peripheral lung lesions［J］.Journal of Clinical Internal Medicine,2022,39（7）：448-452.
［6］张成宪,毛中圆,苏天雄.胸水和血清肿瘤标志物检测在肺癌诊断中的应用价值［J］.当代医学,2021,27(9):100-102. ZHANG CX,MAO ZY,SU TX.The value of detection of pleural fluid and surem tumor markers in the diagnosis of lung cancer［J］.Contemporary Medicine,2021,27（9）：100-102.
［7］VAN DEN HEUVEL M,HOLDENRIEDER S,SCHUURBIERS M,et al.Serum tumor markers for response prediction and monitoring of advanced lung cancer:A review focusing on immunotherapy and targeted therapies［J］.Tumour Biology:the Journal of the International Society for Oncodevelopmental Biology and Medicine,2024,46(s1)：S233-S268.
［8］MOMOKI Y,ICHINOSE A,NAKAMURA K,et al.Development of automatic generation system for lung nodule finding descriptions［J］.PLoS One,2024,19(3)：e0300325.
［9］向青,万涛,胡前方,等.快速现场细胞学评价在EBUS-TBNA取样诊断肺癌中的价值［J］.中国肺癌杂志,2018,21(11):833-840. XIANG Q,WAN T,HU QF,et al.Value of C-ROSE during EBUS-TBNA to obtain the tissue sample in the diagnosis of lung cancer［J］.Chinese Journal of Lung Cancer,2018,21（11）：833-840.
［10］高洁,张伦军,彭珂,等.血清肿瘤标志物CEA,CYFRA21-1,SCCAg,NSE,ProGRP在不同病理分型肺癌诊断中的应用价值［J］.南方医科大学学报,2022,42(06):886-891. GAO J,ZHANG L,PENG K,et al.Diagnostic value of serum tumor markers CEA,CYFRA21-1,SCCAg,NSE and ProGRP for lung cancers of different pathological types［J］.Journal of Southern Medical University,2022,42（6）:886-891.
［11］鞠惠，朱立强，赵利.肿瘤标志物CEA/CYFRA21-1比值联合液基细胞学对非小细胞肺癌分型的诊断价值［J］.医学理论与实践,2020,33(23):4. JU H,ZHU LQ,ZHAO L.The value of serum CEA/CYFRA21-1 ratio combined with brush liquid based cytology in the classification and diagnosis of non-small cell lung cancer［J］.The Journal of Medical Theory and Practice,2020,33（23）：4.
［12］FOWELL A,KHAN K.Impact of rapid on-site evaluation in expediting the fast investigative lung cancer pathway［J］.Cytopathology:Official Journal of the British Society for Clincal Cytology,2024,35(2)：250-255.
［13］ZUCCATOSTA L,ROSSI G,GASPARINI S,et al.Validation of a cytological classification system for the rapid on-site evaluation (rose) of pulmonary and mediastinal needle aspirates［J］.Diagnostics (Basel),2022,12（11）:2777.
［14］YAN S,PAN L,CHEN J,et al.Application of rapid on-site evaluation combined with flexible bronchoscopy in the diagnosis of lung lesions［J］.Annals Diagnostic Pathology,2024,69：152261.
［15］AKHAVE N,ZHANG J,BAYLEY E,et al.Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment［J］.Lung Cancer,2022 （172）:19-28.
［16］BONIFAZI M,SEDIARI M,FERRETTI M,et al.The role of the pulmonologist in rapid on-site cytologic evaluation of transbronchial needle aspiration:a prospective study［J］.Chest,2014,145（1）：60-65.
［17］余立峰,魏修奇,王晖.CEA、CYFRA21-1、SCC和NSE在肺癌诊断、分型、分期和治疗中的综合应用［J］.国际检验医学杂志,2023,44(13):1641-1645. YU LF,WEI XQ,WANG H.Comprehensive application of CEA,CYFRA21-1,SCC and NSE in the diagnosis,classification,staging and treatment of lung cancer［J］.International Journal of Laboratory Medicine,2023,44（13）:1641-1645.
［18］MULEY T,HERTH FJ,HEUSSEL CP,et al.Prognostic value of tumor markers ProGRP,NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission［J］.Tumour Biology:the Journal of the International Society for Oncodevelopmental Biology and Medicine,2024,46(s1)：S219-S232.
［19］KORKMAZ ET,KOKSAL D,AKSU F,et al.Triple test with tumor markers CYFRA 21.1,HE4,and ProGRP might contribute to diagnosis and subtyping of lung cancer［J］.Clinical Biochemistry,2018,58:15-19.
［20］张文秋,李永琦,吴荻.非小细胞肺癌EGFR-TKIs耐药-小细胞肺癌转化的研究进展［J］.中国肺癌杂志,2017,20(10):720-726. ZHANG WQ,LI YQ,WU D.Advances in the transformation to small cell lung cancer from non-small cell lung cancer following acquired drug-resistance to EGFR tyrosine kinase inhibitors［J］.Chinese Journal of Lung Cancer,2017,20（10）：720-726.
［21］SONG XT,CAO LC,NI BY,et al.Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds:From mechanism to clinical practice［J］.Frontiers in Pharmacology,2023,14:1090500.
［22］WU JY,FENG JM,ZHANG QR,et al.Epigenetic regulation of stem cells in lung cancer oncogenesis and therapy resistance［J］.Frontiers Genetics,2023,14：1120815.
［23］MARCU LG,MOGHADDASI L,BEZAK E.Cannot target what cannot be seen:Molecular imaging of cancer stem cells［J］.International Journal of Molecular Sciences,2023,24(2)：1524.
［24］JUUL NH,YOON JK,MARTINEZ MC,et al.KRAS（G12D） drives lepidic adenocarcinoma through stem-cell reprogramming［J］.Nature,2023,619（7971）:860-867.
［25］HAO LD,CHEN HY,WANG LL,et al.Transformation or tumor heterogeneity:Mutations in EGFR,SOX2,TP53,and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer［J］.Thoracic Cancer,2023,14(11)：1036-1041.
［26］KOBAYASHI K,TAN AC.Unraveling the impact of intratumoral heterogeneity on EGFR tyrosine kinase inhibitor resistance in EGFR-mutated NSCLC［J］.International Journal of Molecular Sciences,2023,24（4）:4126.
［27］WANG AG,HAN CP,ZHAO H,et al.Progress in the knowledge on the transformation of lung adenocarcinoma to small-cell lung cancer［J］.Journal of Cancer Research and Therapeutics,2023,19(1):14-19.

Memo

Memo:
贵州省卫健委课题(编号：gzwkj2020-1-170）
Last Update: 1900-01-01